EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors

作者：Yang Liu, Hongyan Wang, Sen Yang, Yuanyuan Yang, Yufeng Wu, Zhen He, Shuxiang Ma, Yuqing Mo, Haiyang Chen, Qiming Wang, Hong Ge · 发表于：Journal of Thoracic Disease · 年份：2022 · DOI：10.21037/jtd-22-755 · 被引用次数：15 · 研究领域：Lung Cancer Treatments and Mutations、Colorectal Cancer Treatments and Studies、Cancer Genomics and Diagnostics

Background: mutational status have different prognosis. Methods: locus, and the cut-off values for 19DEL and L858R were 4.9% and 9.5%, respectively. Results: 0.033) and high mutation abundance (HR: 0.62, 95% CI: 0.50-0.79, P=0.027). Conclusions: mutation types and abundance was associated with the patients' survival which might be used to predict the efficacy of targeted therapy by EGFR-TKIs.